Explore more publications!
Florida Health Daily
Got News to Share?

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on October 24, 2025

Aprende Ayurveda: Online Courses certified by Escuela de Ayurveda de California in Spanish
October 24, 2025

Aprende Ayurveda: Online Courses certified by Escuela de Ayurveda de California in Spanish

Indeterminate EIN Presswire
Dr. Tommy Rhee Redefines Recovery with New Book on Topical Stem Cell Therapy
October 24, 2025

Dr. Tommy Rhee Redefines Recovery with New Book on Topical Stem Cell Therapy

Indeterminate EIN Presswire
Pennant Announces Third Quarter 2025 Earnings Release and Call
October 24, 2025

Pennant Announces Third Quarter 2025 Earnings Release and Call

Indeterminate GlobeNewswire
Enzon and Viskase Announce Amendment to Merger Agreement
October 24, 2025

Enzon and Viskase Announce Amendment to Merger Agreement

Indeterminate GlobeNewswire
60 Iconic Canadian Landmarks to Light Up Blue for World Occupational Therapy Day
October 24, 2025

60 Iconic Canadian Landmarks to Light Up Blue for World Occupational Therapy Day

Indeterminate GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 24, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences
October 24, 2025

Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

Indeterminate GlobeNewswire
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indeterminate GlobeNewswire
Relax in Comfort Launches “Compare the Alternatives” Program to Help Compare Leading Adjustable Smart Mattresses
October 24, 2025

Relax in Comfort Launches “Compare the Alternatives” Program to Help Compare Leading Adjustable Smart Mattresses

Indeterminate EIN Presswire
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
October 24, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Indeterminate GlobeNewswire
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
October 24, 2025

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Indeterminate GlobeNewswire
BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025

BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indeterminate GlobeNewswire
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
October 24, 2025

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Indeterminate GlobeNewswire
Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System
October 24, 2025

Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System

Indeterminate GlobeNewswire
Global Dental Imaging Market to Reach USD 4.69 Billion by 2030 | MarketsandMarkets™
October 24, 2025

Global Dental Imaging Market to Reach USD 4.69 Billion by 2030 | MarketsandMarkets™

Indeterminate GlobeNewswire
AI in Biotechnology Market to Reach $11.4 Billion by 2030
October 24, 2025

AI in Biotechnology Market to Reach $11.4 Billion by 2030

Indeterminate GlobeNewswire
Incubator Stock Review Initiates Coverage on Vystar
October 24, 2025

Incubator Stock Review Initiates Coverage on Vystar

Indeterminate GlobeNewswire
Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
October 24, 2025

Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Indeterminate GlobeNewswire
Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 24, 2025

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indeterminate GlobeNewswire
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
October 24, 2025

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions